China Resources Boya Bio pharmaceutical Group Co Ltd (SHE:300294) — Market Cap & Net Worth
Market Cap & Net Worth: China Resources Boya Bio pharmaceutical Group Co Ltd (300294)
China Resources Boya Bio pharmaceutical Group Co Ltd (SHE:300294) has a market capitalization of $1.16 Billion (CN¥7.91 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #8440 globally and #2074 in its home market, demonstrating a -4.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Resources Boya Bio pharmaceutical Group Co Ltd's stock price CN¥15.68 by its total outstanding shares 504248738 (504.25 Million). Review total liabilities of China Resources Boya Bio pharmaceutical to assess the company's total debt and financial obligations.
China Resources Boya Bio pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
China Resources Boya Bio pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.83 Billion to $1.16 Billion (-4.08% CAGR).
Index Memberships
China Resources Boya Bio pharmaceutical Group Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.43 Trillion | 0.08% | #93 of 100 |
Weight: China Resources Boya Bio pharmaceutical Group Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
China Resources Boya Bio pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.81x
China Resources Boya Bio pharmaceutical Group Co Ltd's market cap is 0.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.80x
China Resources Boya Bio pharmaceutical Group Co Ltd's market cap is 14.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.66 Billion | $946.60 Million | $272.04 Million | 2.81x | 9.77x |
| 2017 | $2.12 Billion | $1.39 Billion | $356.59 Million | 1.53x | 5.95x |
| 2018 | $1.92 Billion | $2.39 Billion | $469.17 Million | 0.80x | 4.09x |
| 2019 | $2.24 Billion | $2.91 Billion | $426.15 Million | 0.77x | 5.25x |
| 2020 | $2.41 Billion | $2.51 Billion | $260.06 Million | 0.96x | 9.27x |
| 2021 | $2.76 Billion | $2.65 Billion | $344.53 Million | 1.04x | 8.01x |
| 2022 | $2.65 Billion | $2.76 Billion | $432.20 Million | 0.96x | 6.12x |
| 2023 | $2.45 Billion | $2.65 Billion | $237.47 Million | 0.92x | 10.32x |
| 2024 | $2.23 Billion | $1.73 Billion | $396.99 Million | 1.29x | 5.63x |
| 2025 | $1.67 Billion | $2.05 Billion | $112.70 Million | 0.81x | 14.80x |
Competitor Companies of 300294 by Market Capitalization
Companies near China Resources Boya Bio pharmaceutical Group Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to China Resources Boya Bio pharmaceutical Group Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
China Resources Boya Bio pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, China Resources Boya Bio pharmaceutical Group Co Ltd's market cap moved from $1.83 Billion to $ 1.16 Billion, with a yearly change of -4.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.16 Billion | -30.62% |
| 2025 | CN¥1.67 Billion | -25.36% |
| 2024 | CN¥2.23 Billion | -8.79% |
| 2023 | CN¥2.45 Billion | -7.39% |
| 2022 | CN¥2.65 Billion | -4.17% |
| 2021 | CN¥2.76 Billion | +14.53% |
| 2020 | CN¥2.41 Billion | +7.83% |
| 2019 | CN¥2.24 Billion | +16.37% |
| 2018 | CN¥1.92 Billion | -9.47% |
| 2017 | CN¥2.12 Billion | -20.14% |
| 2016 | CN¥2.66 Billion | +45.29% |
| 2015 | CN¥1.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of China Resources Boya Bio pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.16 Billion USD |
| MoneyControl | $1.16 Billion USD |
| MarketWatch | $1.16 Billion USD |
| marketcap.company | $1.16 Billion USD |
| Reuters | $1.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more